Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

Novo Nordisk is taking a page out of Eli Lilly’s playbook as the two GLP-1 drugmakers work to fend off compounding pharmacies ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

The home shipments — which will be fulfilled by CenterWell Pharmacy — include Wegovy injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 ...

Shares of Novo Nordisk slipped in Monday morning trading ... trial to see how the drug compared to the company's other drugs, Ozempic, which is approved by the FDA for diabetes, and Wegovy ...

Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...